Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C −/− mice.

Fanconi anemia (FA) is an inherited disorder caused by mutation of one of the 21+ Fanconi DNA-repair genes (1). The FA phenotype may include skeletal anomalies and various carcinomas (2,3). Hematopoietic abnormalities include anemia with progression to BMF in childhood, or clonal progression to AML in adolescence (4). Allogenic stem cell transplantation is the main approach to severe FA hematologic manifestations (5).

Source: Experimental Hematology - March 9, 2022 Category: Hematology Authors: Shirin Hasan, Liping Hu, Olatundun Williams, Elizabeth A. Eklund Source Type: research